EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Calpainopathy (limb-girdle muscular dystrophy type R1): clinical features, diagnostic approaches, and biotechnological treatment methods

Sergey N Bardakov iD, Irina Sorochanu iD, Lilit A Mkrtchyan, Yana S Slesarenko iD, Vadim A Tsargush iD, Igor S Limaev iD, Artur A Isaev iD, Ivan A Yakovlev iD, Roman V Deev iD

Journal of Neuromuscular Diseases · 2025-09 · 12 (5) · 594-618

DOI: 10.1177/22143602251345967 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 02.06.2025. Verfasst von Sergey N Bardakov und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Military Medical Academy named after S.M. Kirov, St. Petersburg, Russia. Hauptthemen laut MEDLINE: Muscular Dystrophies, Limb-Girdle, Calpain. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: State assignment.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Calpainopathy, or limb–girdle muscular dystrophy type R1/2A (LGMDR1/2A), is the most prevalent form of LGMD, comprising about 32% of all cases. The disease is caused by mutations in the CAPN3 gene, leading to dysfunction of the corresponding protein–an enzyme critical for muscle fiber cytoskeleton remodeling and protein signaling regulation through selective proteolysis. Clinical manifestations demonstrate significant phenotypic polymorphisms, ranging from oligosymptomatic forms to severe early-onset cases, with the loss of ambulation occurring 10–25 years after disease onset. A characteristic feature is predominantly symmetrical involvement of limb and trunk muscles, leading to early mobility loss, disability, and reduced work capacity. Noninvasive imaging can suggest dystrophic muscle disease but requires differentiation from other myopathies. Confirming the diagnosis involves histological, immunological, and molecular genetic studies to identify calpain-3 activity or CAPN3 gene expression alterations. Currently, no targeted or etiological therapies are available for calpainopathy. Treatment focuses on symptom management, complication prevention, and slowing disease progression. Preclinical research demands the development of an appropriate animal model that displays disease phenotypes mirroring those observed in humans. Preclinical and clinical research are also investigating therapeutic options, including the use of drugs that have proven effective in other myopathies and genome editing via transgenic CAPN3 delivery to restore protein activity. Gene therapy has shown promise in murine models, but safety concerns, particularly systemic toxicity affecting the heart and other organs, remain significant. This review comprehensively analyzes the clinical features, diagnostic approaches, and advancements in modeling and therapeutic development for calpainopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophies, Limb-GirdleCalpainHumansAnimalsMuscle Proteins

Stichwörter der Autor:innen

calpainopathyclinical characteristicsdiagnosisgene therapylimb–girdle muscular dystrophy type R1/2A (LGMDR1/2A)pharmacotherapy

Substanzen

CalpainCAPN3 protein, humanMuscle Proteins

Autor:innen und Institutionen

  • Department of Neurology, Military Medical Academy named after S.M. Kirov, St. Petersburg, Russia.
  • Genotarget LLC, Skolkovo Innovation Center, Moscow, Russia.
  • Faculty of Medicine, North-Western State Medical University named after I.I. Mechnikov, St. Petersburg, Russia.
  • Avtsyn Research Institute of Human Morphology of Petrovsky National Research Centre Of Surgery, Moscow, Russia.
  • Artgen biotech PJSC, Moscow, Russia.

ORCID-Profile: Sergey N Bardakov, Irina Sorochanu, Yana S Slesarenko, Vadim A Tsargush, Igor S Limaev, Artur A Isaev, Ivan A Yakovlev, Roman V Deev

Förderung

  • State assignment

Zitieren

APA

Bardakov, S. N., Sorochanu, I., Mkrtchyan, L. A., Slesarenko, Y. S., Tsargush, V. A., Limaev, I. S., Isaev, A. A., Yakovlev, I. A., & Deev, R. V. (2025). Calpainopathy (limb-girdle muscular dystrophy type R1): clinical features, diagnostic approaches, and biotechnological treatment methods. Journal of Neuromuscular Diseases, 12(5), 594-618. https://doi.org/10.1177/22143602251345967

Vancouver

Bardakov SN, Sorochanu I, Mkrtchyan LA, Slesarenko YS, Tsargush VA, Limaev IS, et al. Calpainopathy (limb-girdle muscular dystrophy type R1): clinical features, diagnostic approaches, and biotechnological treatment methods. Journal of Neuromuscular Diseases. 2025;12(5):594-618. doi:10.1177/22143602251345967

BibTeX
@article{Bardakov2025,
  author = {Bardakov, Sergey N and Sorochanu, Irina and Mkrtchyan, Lilit A and Slesarenko, Yana S and Tsargush, Vadim A and Limaev, Igor S and Isaev, Artur A and Yakovlev, Ivan A and Deev, Roman V},
  title = {Calpainopathy (limb-girdle muscular dystrophy type R1): clinical features, diagnostic approaches, and biotechnological treatment methods},
  journal = {Journal of Neuromuscular Diseases},
  year = {2025},
  volume = {12},
  number = {5},
  pages = {594--618},
  doi = {10.1177/22143602251345967}
}
Kostenlos starten →